ReviewScience China. Life sciences2026
Deubiquitinases in liver diseases: from mechanisms to targeted therapy.
Review in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Correspondence to editorial on "RAB25/GCN1 signaling promotes endoplasmic reticulum stress to mediate alcohol-associated liver disease progression".Clinical and molecular hepatology · 2026Article
- Deubiquitinating Enzymes as Therapeutic Candidates in Hepatocellular Carcinoma and Other Liver Disease.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fatty liver disease, hepatitis, hepatocellular carcinoma (HCC), and other major liver diseases are significant global public health challenges. A deeper understanding of the underlying mechanisms driving the onset and progression of these diseases, along with the exploration of potential targeted therapies, is of critical importance. The ubiquitin-proteasome system (UPS) plays a crucial role in protein degradation in eukaryotic cells. Deubiquitinases (DUBs) are key enzymes that regulate the balance between ubiquitination and deubiquitination, and they are involved in a wide range of cellular physiological processes. Dysregulation of DUBs is frequently observed in various liver diseases, including chronic liver diseases (CLDs) and HCC. Targeted therapies, with their high selectivity and low side effects, have attracted significant attention. Small molecules targeting DUBs have shown promising therapeutic effects in the treatment of major liver diseases. Given the important role of DUBs in liver diseases, this review focuses on summarizing the potential mechanisms through which DUBs contribute to the development of metabolic dysfunction-associated steatotic liver disease (MASLD), viral hepatitis, liver fibrosis, and HCC, as well as the application of DUB inhibitors. It aims to provide a theoretical foundation for basic research on major liver diseases and propose strategies for their treatment.
Indexed as
Identifiers
41284188What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.